New Immunomodulatory Therapeutic Vaccine that Targets Oligomeric Amyloid-β Could be Step Towards Halting Alzheimer’s Disease Progression
27. Oktober 2020 06:56 ET
|
Alzamend Neuro, Inc.
TAMPA, Fla., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Alzheimer’s disease affects more than 5.8 million Americans at an estimated cost at over $305 billion in 2020 according to the Alzheimer's Association....
Alzamend Neuro™ Completes New Management Team for 2019
26. Dezember 2018 09:00 ET
|
Alzamend Neuro, Inc.
Tampa, Fla., Dec. 26, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed top-tier financial executive, Kenneth S. Cragun, CPA, as its...
Alzamend Neuro™ Appoints New CEO, Bio-Pharma Executive Stephan Jackman
20. November 2018 09:00 ET
|
Alzamend Neuro, Inc.
Salt Lake City, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed bio-pharma executive, Mr. Stephan Jackman, as its new Chief...
Alzamend Neuro™ Secures New Licenses from USF to Treat Alzheimer’s Disease
29. Oktober 2018 09:00 ET
|
Alzamend Neuro, Inc.
Salt Lake City, UT, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it secured two new licenses from the University of South Florida (“USF”)...
Alzamend Neuro™ Launches Pursuit to Secure FDA IND and First Stage Clinicals
24. Oktober 2017 22:35 ET
|
Alzamend Neuro, Inc.
SALT LAKE CITY, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has selected TAMM Net of Marietta, GA to lead its FDA regulatory...
USF Researcher Develops Therapeutic Vaccine to Combat Alzheimer’s Disease and Neurodegenerative Disorders
30. Januar 2017 06:00 ET
|
Alzamend Neuro, Inc.
SALT LAKE CITY, Jan. 30, 2017 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) reprints by permission of the University of South Florida (USF) Technology Transfer Office this...
Alzamend Neuro™ Announces TV Icon Willie Aames as International Spokesperson
09. Januar 2017 06:00 ET
|
Alzamend Neuro, Inc.
SALT LAKE CITY, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today Willie Aames will serve as its International Spokesperson while joining the team...
Alzamend Neuro Launches Regulation A+ Tier II SEC Qualified Offering
03. Januar 2017 14:05 ET
|
Alzamend Neuro, Inc.
SALT LAKE CITY, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Alzamend) announced today it has launched its Regulation A+ Tier II Offering online at www.AlzamendRegA.com. The Company’s...